Search

Displaying results 2791 - 2800 of 10000 in total
  1. Drug

    Streptococcus pneumoniae type 1 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10319
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: Prevnar 20, SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTOR
  2. Drug

    Streptococcus pneumoniae type 6b capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10324
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: Prevnar 20, SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTOR
  3. Drug

    Streptococcus pneumoniae type 7f capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10325
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: Prevnar 20, SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTOR
  4. Drug

    Streptococcus pneumoniae type 9v capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10328
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: Prevnar 20, SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTOR
  5. Drug

    Streptococcus pneumoniae type 19f capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10336
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: Prevnar 20, SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTOR
  6. Drug

    Gatralimab

    go.drugbank.com/drugs/DB16528
    Investigational

    Gatralimab is under investigation in clinical trial NCT02389452 (Study of Safety and Efficacy of 6 Ml Synvisc-one (Hylan G-F 20) in Indian Patients With Symptomatic Osteoarthritis of Knee(s) After Initial

  7. Drug

    Mirvetuximab soravtansine

    go.drugbank.com/drugs/DB12489
    ApprovedInvestigational

    [L43967,L43972] It was subsequently granted full approval in March 2024.[L50306] In October 2024, it was approved in the EU for the same indication. [L52640] … [A254382] After an ADC/receptor complex is formed, mirvetuximab soravtansine-gynx is internalized, and DM4 is released inside the cell.

  8. Drug

    Brentuximab

    go.drugbank.com/drugs/DB05471
    Investigational

    SGN-30 received orphan drug designation from the FDA in July 2003 for Hodgkin lymphoma and in February 2004 for T-cell lymphomas. … We are collaborating with the National Cancer Institute (NCI) on three clinical trials of SGN-30 in combination with chemotherapy for the treatment of relapsed Hodgkin lymphoma, front-line ALCL and pediatric

  9. Drug

    Demeclocycline

    go.drugbank.com/drugs/DB00618
    Approved

    A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.

  10. Drug

    Bromfenac

    go.drugbank.com/drugs/DB00963
    ApprovedWithdrawn

    Non-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.[L43942,T239] … Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool for optimizing surgical outcomes.